RecruitingPhase 2NCT07064707

Rupatadine in Patients With Ulcerative Colitis

Clinical Study to Evaluate Safety and Efficacy of Rupatadine in Patients With Ulcerative Colitis.

Sponsor

Alexandria University

Enrollment

60 participants

Start Date

Jul 15, 2025

Study Type

INTERVENTIONAL

Conditions

Ulcerative Colitis

Summary

Ulcerative colitis (UC) is a chronic inflammatory condition that primarily targets the large intestine. Although substantial progress has been made in treatment modalities-especially with the development of immunomodulatory drugs and biologic therapies-managing UC continues to present significant challenges. At present, there is no definitive cure, and current treatment strategies are largely focused on controlling inflammation, relieving symptoms, and halting disease progression

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether rupatadine — an antihistamine and anti-inflammatory medication — can help reduce symptoms and inflammation in people with mild to moderate ulcerative colitis (a chronic inflammatory bowel condition affecting the large intestine). **You may be eligible if...** - You are 18 years or older (male or female) - You have mild or moderate ulcerative colitis confirmed by endoscopy (a camera procedure to look inside the colon) and biopsy **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have colorectal cancer - You have severe ulcerative colitis - You are taking rectal or systemic steroids - You are using immunosuppressive drugs or biological therapies (such as infliximab) - You have an alcohol or drug addiction - You have a known allergy to the study medications Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMesalamine

Mesalamine or 5-amino salicylic acid (5-ASA), plays a crucial role in the treatment of ulcerative colitis (UC). It is the first-line therapy for mild to moderate cases of UC and is considered a cornerstone in its management.

DRUGRupatadine

Rupatadine, a dual histamine H1 receptor and platelet-activating factor (PAF) receptor antagonist, has shown promising anti-inflammatory effects beyond its conventional use in allergic conditions

Locations(1)

Alexandria University

Alexandria, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07064707

Related Trials

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

NCT0697933682 locations

A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice

NCT0696411319 locations

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

NCT0718500920 locations

A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

NCT0544256798 locations

Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population

NCT071772091 location